Not recruiting
Follicular lymphoma
Not recruitingPhase II Study of ME-401, Rituximab and Bendamustine as First‑Line Treatment for High‑Risk and Low‑Risk Follicular Lymphoma Patients
Registered drugNo placebo
Phase II Study of ME-401, Rituximab and Bendamustine as First‑Line Treatment for High‑Risk and Low‑Risk Follicular Lymphoma Patients
Registered drugNo placebo
- Disease:Follicular lymphoma
- Substances:BendamustineME-401+1
Countries:
Sweden
Sweden- Participants:18–64 years · 65+ years
- Substances:Bendamustine
